Back to News
Market Impact: 0.25
Ligand Buys Royalty Rights In Santen's Ryjunea Eye Drug
Source: Nasdaq
M&A & RestructuringHealthcare & BiotechCompany Fundamentals
Ligand Pharmaceuticals acquired royalty and milestone-payment rights linked to Santen Pharmaceutical's Ryjunea, the first approved drug treatment in Europe and the UK designed to slow myopia progression in children. The transaction expands Ligand's portfolio of royalty-based healthcare assets, though no purchase price or expected financial contribution was disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
LGND0.65
More News
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- The AI ‘credit card’ is getting costlier as CoreWeave bond yield tops 16%
- OpenAI to press ahead with data-center expansion despite midterm sweep, CFO tells CNBC
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- FIGS Beats Earnings as Demand Outstrips Supply, CEO Trina Spear Says
- SoftBank, ABB consider China carve-out to rescue $5.4bn robotics deal